Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 20/20 | 1.00 |
| ▸ | CXCR2 | P25025 | 20/20 | 1.00 |
| ▸ | CXCR3 | P49682 | 4/20 | 1.00 |
| ▸ | CCR6 | P51684 | 3/20 | 1.00 |
| ▸ | CCR4 | P51679 | 1/20 | 1.00 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.55 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.55 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18310043 | 0.81 | CXCR2 (0.80) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL13808747 | 0.78 | CXCR2 (0.64) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL14895346 | 0.71 | CXCR1 (1.00) | CXCR1CXCR2CXCR3CCR6CXCR6 | |
| SCHEMBL12310859 | 0.69 | CXCR2 (0.64) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL14511375 | 0.63 | CXCR2 (0.78) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL13243271 | 0.61 | CXCR2 (0.83) | CXCR1CXCR2CCR6 | |
| SCHEMBL14895076 | 0.61 | CXCR1 (0.41) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL12086856 | 0.60 | CXCR2 (0.78) | CXCR1CXCR2CCR6 | |
| SCHEMBL18310042 | 0.59 | CXCR1 (0.39) | CXCR1CXCR2CXCR3CCR6CCR4 | |
| SCHEMBL12263314 | 0.58 | CXCR1 (0.90) | CXCR1CXCR2CXCR3CCR6CXCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580412-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-02-28 | — | — | US | disclosed |
| US-9580412-B2 | Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-02-28 | — | — | US | disclosed |